Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that IL-17A-producing γδ T cells play a key role in bone fracture healing by promoting bone formation, with deficiencies leading to impaired repair in mice.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This study observed that in aged mouse skin, there was an increase in IL-17-expressing T helper cells, γδ T cells, and innate lymphoid cells, and blocking IL-17 signaling reduced skin inflammation and delayed age-related changes, suggesting it as a potential target to mitigate skin aging.

This study found that targeting IL-6, IL-1, and CCR6 signaling pathways may effectively reduce irradiation-induced alopecia and dermatitis in radiotherapy patients.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.

This study found IL-17/IL-36 signaling to be predominant in both endotypes of Netherton syndrome, with distinct molecular profiles between NS-ILC and NS-SE lesions, offering potential therapeutic targets.

This study found that CXCL12+ fibroblast subsets in mouse skin play a critical role in recruiting neutrophils and defending against S. aureus infection, with similar fibroblast activity observed in human psoriatic skin.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

This study found that acne lesions and nonlesional skin in mild-to-moderate acne patients showed significant Th17-skewing and increased antimicrobials, suggesting systemic targets like IL-17/IL-23/IL-36 could be therapeutic.

This study found that in a mouse model of Ross River virus-induced joint inflammation, targeting IL-17A and IL-17A/F heterodimers reduced disease severity.

This study found that patients with psoriasis had a significantly higher prevalence of autoimmune diseases and other comorbidities compared to individuals without psoriasis.

This study suggests that Notch1 acts as a key signal in skin epithelium, promoting immune cell recruitment and aiding in normal skin repair after damage.

This study explored hair follicle gene expression in Inner Mongolia Cashmere goats and identified potential regulators of the transition between growth phases, including IL17RB and ZNF genes.

This study found that γδ T cells play a role in regulating stromal behavior, influencing the composition and vascularity of fibrotic tissues during the foreign body response.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.

This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This study found that specific gene upregulations and mutations in hidradenitis suppurativa skin support the role of inflammation, altered epithelial differentiation, and metabolism dysregulation in the disease's pathogenesis.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

This study found that IL-1α promotes hair follicle regeneration and stem cell activation in an age-dependent manner by modulating inflammatory cells and oxidative stress in mice.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

This study found that while Platelet Rich Plasma injections led to some clinical and immunological improvements in psoriatic plaques, it could not be recommended as a standalone treatment for localized plaque psoriasis.

This case report describes a 50-year-old woman with palmoplantar psoriasis who developed alopecia areata after starting tildrakizumab, suggesting a possible paradoxical reaction related to the medication.

In this study, increased Treg cell activity indicated by IL-10 and IL-15 was identified as a feature of ADTA, distinguishing it from AA and potentially explaining ADTA's more favorable prognosis.

This research notes that biologics and small molecules are effective for treating nail psoriasis and alopecia areata, albeit with precautions for adverse events, but no clinical trials have been published for their use in treating nail lichen planus and atopic dermatitis.